Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies
Authors' conclusion
Our data show that combination of RTX and MMF is effective and safe in patients with severe and refractory IIM.
Study context
- Population
- Patients with idiopathic inflammatory myopathies (IIM) (anti-synthetase syndrome most prevalent, 60%) treated with rituximab (RTX)/mycophenolate mofetil (MMF) combination; median age 61 years; 70% female
- Participants
- 20 patients
- Outcome
- Efficacy per 2016 ACR/EULAR response criteria for IIM
- Follow-up
- 12 months (T12)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Moderate or major response (2016 ACR/EULAR criteria) · 12 months
- Moderate or major response observed in all patients
Observational data: associations, not effects.
Further findings
Creatine kinase · 12 months
- Significantly decreased
- P = 0.012
Heart inflammation (cardiac imaging and enzymes)
- Reduction of heart inflammation
Pulmonary function tests in patients with lung involvement
- Improved
Safety
- No severe side effects observed
Original publication
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies. Arthritis Res Ther. Published 3 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →